Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
Language English Country United States Media electronic
Document type Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
KL2 TR002002
NCATS NIH HHS - United States
R21 TR003587
NCATS NIH HHS - United States
U54 CA224019
NCI NIH HHS - United States
PubMed
37607920
PubMed Central
PMC10444844
DOI
10.1038/s41408-023-00898-4
PII: 10.1038/s41408-023-00898-4
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute * drug therapy genetics MeSH
- Drug Resistance, Neoplasm * genetics MeSH
- Forkhead Box Protein M1 genetics MeSH
- Nuclear Proteins genetics MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Names of Substances
- Forkhead Box Protein M1 MeSH
- FOXM1 protein, human MeSH Browser
- Nuclear Proteins MeSH
Centro Nacional de Investigaciones Oncológicas Madrid Spain
Computational and Systems Biology University of Pittsburgh Pittsburgh PA USA
OHSU Knight Cancer Institute School of Medicine Portland OR USA
Robert H Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA
The Czech Advanced Technology and Research Institute of Palacký University Olomouc Czech Republic
University of Groningen Groningen Netherlands
University of Illinois at Chicago Department of Medicine Chicago IL USA
See more in PubMed
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl J Med. 2005;352:254–66. doi: 10.1056/NEJMoa041974. PubMed DOI
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803. doi: 10.1182/blood.2019003988. PubMed DOI PMC
Bhat UG, Jagadeeswaran R, Halasi M, Gartel AL. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J Biol Chem. 2011;286:41425–33. doi: 10.1074/jbc.M111.270843. PubMed DOI PMC
Khan I, Halasi M, Zia MF, Gann P, Gaitonde S, Mahmud N, et al. Nuclear FOXM1 drives chemoresistance in AML. Leukemia. 2017;31:251–5. doi: 10.1038/leu.2016.270. PubMed DOI
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.. doi: 10.1038/nm.3909. PubMed DOI PMC
Chesnokov MS, Borhani S, Halasi M, Arbieva Z, Khan I, Gartel AL. FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML. Front Oncol. 2021;11:696532. doi: 10.3389/fonc.2021.696532. PubMed DOI PMC
Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, et al. FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018;3:e121583. doi: 10.1172/jci.insight.121583. PubMed DOI PMC
Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS ONE. 2009;4:e6593. doi: 10.1371/journal.pone.0006593. PubMed DOI PMC
Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, et al. Honokiol is a FOXM1 antagonist. Cell Death Dis. 2018;9:84. doi: 10.1038/s41419-017-0156-7. PubMed DOI PMC
Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinković D, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014;5:5165. doi: 10.1038/ncomms6165. PubMed DOI PMC
Sun L, Ren X, Wang IC, Pradhan A, Zhang Y, Flood HM, et al. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017;10:eaai8583. doi: 10.1126/scisignal.aai8583. PubMed DOI
Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850–64.e9. doi: 10.1016/j.ccell.2022.07.002. PubMed DOI PMC
Chesnokov MS, Halasi M, Borhani S, Arbieva Z, Shah BN, Oerlemans R, et al. Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. Cell Death Dis. 2021;12:704. doi: 10.1038/s41419-021-03978-0. PubMed DOI PMC
Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, et al. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. Cancer Discov. 2023;13:746–65. doi: 10.1158/2159-8290.CD-22-0366. PubMed DOI PMC
Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, et al. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov. 2023;13:724–45. doi: 10.1158/2159-8290.CD-22-0424. PubMed DOI PMC
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
